期刊
CIRCULATION RESEARCH
卷 128, 期 10, 页码 1554-1575出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.121.318187
关键词
amyloidosis; biopsy; cardiomyopathy; incidence; light chain; prevalence; rare disease; transthyretin
资金
- National Institutes of Health [HL139671-01, AG R21AG058348, AG K24AG036778]
Cardiac amyloidosis, once considered a rare disease, is now increasingly recognized due to aging population and noninvasive diagnostic methods. Better understanding of the pathogenesis of cardiac amyloidosis has led to the development of multiple effective therapies.
Often considered a rare disease, cardiac amyloidosis is increasingly recognized by practicing clinicians. The increased rate of diagnosis is in part due the aging of the population and increasing incidence and prevalence of cardiac amyloidosis with advancing age, as well as the advent of noninvasive methods using nuclear scintigraphy to diagnose transthyretin cardiac amyloidosis due to either variant or wild type transthyretin without a biopsy. Perhaps the most important driver of the increased awareness is the elucidation of the biologic mechanisms underlying the pathogenesis of cardiac amyloidosis which have led to the development of several effective therapies with differing mechanisms of actions. In this review, the mechanisms underlying the pathogenesis of cardiac amyloidosis due to light chain (AL) or transthyretin (ATTR) amyloidosis are delineated as well as the rapidly evolving therapeutic landscape that has emerged from a better pathophysiologic understanding of disease development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据